Association of HER-2/neu overexpression with the number of involved axillary lymph nodes in hormone receptor positive breast cancer patients

Experimental Oncology

Volumn 27, Issue 2, 2005, Pages 145-149

  Fusun, Tokatli ^a   Semsi, Altaner ^a   Cem, Uzal ^a   Mevlut, Ture ^a   Zafer, Kocak ^a   Kazim, Uygun ^a   Selcuk, Bilgi ^a  

^a TRAKYA UNIVERSITY   (Turkey)

Author keywords

Axillary lymph node involvement; Breast cancer; HER 2 neu; Prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE RECEPTOR; PROTEIN P53;

ADULT; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER INVASION; CANCER SURVIVAL; CLINICAL ARTICLE; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; FEMALE; GENE AMPLIFICATION; GENE FUNCTION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MULTIVARIATE ANALYSIS; ONCOGENE NEU; PREDICTION; PROGNOSIS; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; AXILLA; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPH NODES; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 22644435284     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Agrup M, Stal O, Olsen K, Wingren S. C-erbB-2 overexpression and survival in early onset breast cancer. Breast Cancer Res Treat 2000; 63: 23-9.
2. th ed. Philadelphia: Lippincott-Raven; 1997.
3. Banerjee SK, Zoubime MN, Mullick M, Weston AP, Cherian R, Campbell DR. Tumour angiogenesis in chronic pancreatitis and pancreatic adenocarcinoma: Impact of K-ras mutations. Pancreas 2000; 20: 248-55.
4. Bloom HJC, Richardson WW. Histological grading and prognosis in breast cancer: A study of 1049 cases, of which 359 have been followed 15 years. Br J Cancer 1957; 11: 359-77.
5. Charpin C, Garcia S, Bouvier C, Martini F, Lavaut MN, Allasia C, Bonnier P, Andrac L. c-erbB-2 oncoprotein detected by automated quantitative immunocytochemistry in breast carcinomas correlates with patients' overall and disease-free survival. Br J Cancer 1997; 75: 1667-73.
6. Climent MA, Segui MA, Peiro G, Molina R, Lerma E, Ojeda B, Lopez-Lopez JJ, Alonso C. Prognostic value of HER-2/neu and p53 expression in node-positive breast cancer. HER-2/neu effect on adjuvant tamoxifen treatment. Breast 2001; 10: 67-77.
7. Cox DR. Regression models and life tables. J R Stat Soc Bull 1972; 34: 187-202.
8. Dandachi N, Dietze O, Hauser-Kronberger C. Evaluation of the clinical significance of HER2 amplification by chromogenic in situ hybridization in patients with primary breast cancer. Anticancer Res 2004; 24: 2401-6.
9. Gasparini G, Weidner N, Bevilacqua P, Maluta S, Palma PD, Caffo O, Barbareschi M, Boracchi P, Marubini E, Pozza F. Tumour microvessel density, p53 expression, tumour size, and peritumoural lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 1994; 12: 454-66.
10. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
11. McCann AH, Dervan PA, O'Regan M, Codd MB, Gullick WJ, Tobin BMJ, Carney DN. Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer. Cancer Res 1991; 51: 3296-303.
12. Mittra I, Redkar AA, Badwe RA. Prognosis of breast cancer: evidence for interaction between c-erbB-2 overexpression and number of involved axillary lymph nodes. J Surg Oncol 1995; 60: 106-11.
13. Paulett G, Godolphin W, Press MF, Slamon DJ. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 1996; 13: 63-72.
14. Pawlowski V, Revillion F, Hebbar M, Hornez L, Peyrat JP. Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res 2000; 6: 4217-25.
15. Ray A, Sharma BK, Kaur S, Sharma S, Sharma JK. Overexpression of c-erbB-2 oncoprotein and associated pathobiological factors in invasive primary breast cancer. Indian J Exp Biol 2004; 42: 253-8.
16. Ribeiro-Silva A, Leandra N, Ramalho Z, Garcia SB, Zucoloto S. The relationship between p63 and p53 expression in normal and neoplastic breast tissue. Arch Pathol Lab Med 2003; 127: 336-40.
17. Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, Symmans WF, Pusztai L, Bloom KJ. The HER-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. The Oncologist 2003; 8: 307-25.
18. Rudolph P, Olsson H, Bonatz G, Ratjen V, Bolte H, Baldetorp B, Ferno M, Parwaresch R, Alm P. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications. J Pathol 1999; 187: 207-16.
19. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82.
20. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 701-12.
21. Thor AD, Liu S, Edgerton S, Moore II D, Kasowitz KM, Benz CC, Stern DF, DiGiovanna MP. Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer. J Clin Oncol 2000; 18: 3230-9.
22. Tsutsui S, Ohno S, Murakami S, Hachitanda Y, Oda S. Prognostic value of c-erbB2 expression in breast cancer. J Surg Oncol 2002; 79: 216-23.
23. Zhang D, Salto-Tellez M, Do E, Putti TC, Koay ES. Evaluation of HER-2/neu oncogene status in breast tumours on tissue microarrays. Hum Pathol 2003; 34: 362-8.
24. Zhang D, Salto-Tellez M, Putti TC, Do E, Koay ES. Reliability of tissue microarrays in detecting protein expression and gene amplification in breast cancer. Mod Pathol 2003; 16: 79-85.